Eli Lilly ties up 2022 by expanding deal with battered RNA-editing biotech
Despite a year littered with setbacks, ProQR Therapeutics is closing 2022 on a high note.
The Dutch biotech is expanding its RNA editing collaboration with Eli Lilly, with a potentially large payoff down the line, the companies announced early Thursday morning.
Lilly is putting down $75 million in upfront cash and equity, with a $50 million option to expand the deal further in the future. There’s also now $3.75 billion in biobucks on the table, compared with $1.25 billion when the pair signed their original deal in September 2021.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.